Meghan Sullivan
Nurse Practitioner · Saint Louis, MONPI 1740694074
Payments from drug & device makers
Across 464 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Gilead$663
- Merck$555
- Novo Nordisk$462
- Lilly USA, LLC$451
- Viiv Healthcare Company$418
- plus $4K from 54 others
What the payments were for
- Speaking & faculty fees$120%
- Food & beverage$7,85698%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,987 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 122 | $545,318 |
| CabenuvaCabotegravir/Rilpivirine | 13 | $70,659 |
| DescovyEmtricitabine/Tenofov Alafenam | 22 | $52,707 |
| JulucaDolutegravir/Rilpivirine | 14 | $52,177 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $43,217 |
| PifeltroDoravirine | 22 | $39,677 |
| TivicayDolutegravir Sodium | 13 | $33,784 |
| OzempicSemaglutide | 29 | $31,469 |
| RybelsusSemaglutide | 18 | $27,076 |
| JardianceEmpagliflozin | 17 | $17,425 |
| EliquisApixaban | 25 | $15,781 |
| FarxigaDapagliflozin Propanediol | 20 | $12,586 |
| Testosterone | 50 | $11,090 |
| JanuviaSitagliptin Phosphate | 14 | $8,804 |
| VascepaIcosapent Ethyl | 21 | $8,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $663 | $598,025144 claims |
| Viiv Healthcare CompanyCabenuva, Juluca, Tivicay | $418 | $156,62040 claims |
| Novo NordiskOzempic, Rybelsus | $462 | $58,54547 claims |
| MerckPifeltro, Januvia | $555 | $48,48136 claims |
| Boehringer IngelheimJardiance | $16 | $17,42517 claims |
| PfizerEliquis | $414 | $15,78125 claims |
| AstraZenecaFarxiga | $290 | $12,58620 claims |
| Clarus Therapeutics Inc.Jatenzo | $44 | $5,89611 claims |
| GSKIncruse Ellipta | $116 | $4,95014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Saint Louis
- Carrie Roth BettlachSaint Louis$21K
- Lisa CampbellSaint Louis$16K
- Angela VickroySaint Louis$15K
- Isabel HartigSaint Louis$13K
- Kathryn LindsaySaint Louis$13K
- Leanna ScheidemantelSaint Louis$12K
- Samra FajicSaint Louis$12K
- Debra GaseSaint Louis$11K
- Kristin DalySaint Louis$11K
- Kimbra CardwellSaint Louis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.